SIK2 and neoplasm: Together, our results demonstrate the efficiency and potency of the newly designed SIK2 inhibitor MRIA9 and confirm the benefit of combining SIK2 inhibition with a taxane-based treatment as a new tumor-suppressing strategy in this highly lethal gynecological disease.